Microsatellite instability-high in stage IV colorectal cancer: prevalence, and clinicopathological characteristics in Malaysia
Aim: The purpose of this study was to estimate the prevalence of Microsatellite Instability High (MSI-H) in stage IV colorectal cancer in Malaysians and to describe MSI-H clinicopathological characteristics. Method: All patients with stage IV colorectal cancer who underwent surgical resection of th...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
John Wiley & Sons
2024
|
Subjects: | |
Online Access: | http://irep.iium.edu.my/114821/1/114821_Microsatellite%20instability-high%20in%20stage%20IV.pdf http://irep.iium.edu.my/114821/ https://onlinelibrary.wiley.com/doi/10.1111/codi.17125 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universiti Islam Antarabangsa Malaysia |
Language: | English |
Summary: | Aim: The purpose of this study was to estimate the prevalence of Microsatellite Instability High (MSI-H) in stage IV colorectal cancer in Malaysians and to describe MSI-H clinicopathological characteristics.
Method: All patients with stage IV colorectal cancer who underwent surgical resection of the primary tumor between January 2017 and December 2020 were included in the single-center retrospective study. MSI status was determined. Clinicopathological features were evaluated.
Results: Among 42 patients with stage IV colorectal cancer, 4 patients (10%) had MSI-H (57% were men) with an average age of 58 ± 21 years and were related to left-sided colonic origin, adenocarcinoma, moderately differentiated, lymphovascular invasion, single-organ metastasis, peritoneal metastasis, and Malay race. The average survival durations for MSI-H and Microsatellite Stable (MSS) were 15 ± 14 and 18 ± 16 months, respectively (p= 0.77).
Conclusion: In this study, MSI-H was detected in 10% of individuals with stage IV colorectal cancer. However, our data highlight the features and prognostic relevance of MSI-H in Malaysian stage IV colorectal cancer patients. |
---|